此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

FLOAT for Healthcare PTSS (PTSS FLOAT)

2026年7月13日 更新者:adrienne taren、Laureate Institute for Brain Research, Inc.

Neural Mechanisms of Floatation-REST Therapy for Post-Traumatic Stress Symptoms in Frontline Healthcare Workers

This early-stage pilot trial aims to examine the feasibility, tolerability, and safety of Floatation-REST, or Reduced Environmental Stimulation Therapy via floatation in frontline healthcare workers, first responders, and emergency medical personnel who experience post-traumatic stress symptoms.

研究概览

详细说明

Frontline healthcare workers, first responders, and emergency medical personnel are repeatedly exposed to occupational stressors and potentially traumatic events, placing them at elevated risk for post-traumatic stress symptoms (PTSS), burnout, anxiety, and related impairments. Current stress-reduction approaches for healthcare workers often have limited evidence for efficacy or may be difficult to implement in high-demand emergency and healthcare settings. Therefore, rapid, low-burden interventions that are feasible, tolerable, and safe for this population are needed.

Floatation-REST, or Reduced Environmental Stimulation Therapy, is a non-pharmacological intervention that reduces sensory input to the nervous system through the act of floating supine in a pool of warm water saturated with Epsom salt. The float environment is designed to reduce visual, auditory, thermal, tactile, vestibular, and proprioceptive stimulation. Prior studies suggest that Floatation-REST may acutely reduce stress and anxiety-related symptoms, but it has not yet been systematically evaluated in frontline healthcare workers with elevated PTSS.

This single-site, double-arm pilot study will examine the feasibility, tolerability, and safety of two 60-minute sessions of Floatation-REST compared with a documentary-viewing condition in adults ages 18 to 64 with work-related post-traumatic stress symptoms. Up to 30 participants will be recruited, with the goal of retaining 15 completers randomized on a 2:1 basis to Floatation-REST versus comparator condition. Participants will complete two in-person study visits at the Laureate Institute for Brain Research, including self-report questionnaires, blood and saliva collection, functional magnetic resonance imaging scans, and either Floatation-REST or documentary viewing. Follow-up surveys will be completed virtually up to one week after final intervention session.

The primary aim is to evaluate the safety and tolerability of Floatation-REST in this population. Secondary aims will explore whether Floatation-REST is associated with acute changes in PTSS, perceived stress, anxiety, burnout, mood, mindfulness, and moral injury-related distress. Exploratory aims will examine whether changes in brain network connectivity, salivary cortisol, and blood-based proteomic markers may help explain symptom change. Results from this early-stage study will help determine whether Floatation-REST should be further studied as a potential intervention for post-traumatic stress symptoms in frontline healthcare and emergency personnel.

研究类型

介入性

注册 (估计的)

15

阶段

  • 第一阶段早期

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Oklahoma
      • Tulsa、Oklahoma、美国、74136
        • 招聘中
        • Laureate Institute for Brain Research
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Work-related post-traumatic stress dysfunction as measured by either of the following inclusion pathways:

    (A) PTSS Pathway: PCL-5 greater than or equal to 20, OR meets criteria for full or partial PTSD on the MINI International Neuropsychiatric Interview 7 (DSM-V) (Criteria A + at least 2 B-E Criteria) OR (B) Functionally Anchored Pathway: evidence of work-related trauma exposure on the MINI International Neuropsychiatric Interview 7 (DSM-V) (Criterion A) or Life Events Checklist-5, and at least one of the following: Moral Injury and Distress Scale greater than or equal to 27, Sheehan Disability Scale greater than or equal to 5 on at least 1 of the 3 subscales, high or very high level of perceived stress (measured by PhenX Perceived Stress Scale greater than or equal to 16).

  2. First responder or other emergency medical personnel
  3. Ability to read, speak and understand English
  4. Capable of providing consent

Exclusion Criteria:

  1. History of neurological conditions
  2. Skin conditions or open wounds
  3. DSM-5 diagnosis of psychotic spectrum disorders, obsessive-compulsive disorder, bipolar disorder, severe substance use disorder, or eating disorder
  4. Inability to lay comfortably in a shallow pool of water
  5. Failure to adhere to "pre-float checklist"
  6. Breathalyzer test positive for alcohol or a drug-positive urine test
  7. Unwillingness to provide consent or complete major aspects of protocol
  8. MRI contraindications
  9. Unstable medical diagnoses
  10. Pregnancy
  11. Evidence of inability to comply with study procedures based on experimenter judgement
  12. Change in the dose or prescription of a medication within the 6 weeks before enrolling in the study that could affect brain functioning (e.g., anxiolytics, antipsychotics, antidepressants, benzodiazepines, or mood stabilizers)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Floatation-REST
Participants will float supine in a shallow pool for two one-hour sessions approximately seven days apart.
Participants float supine in a shallow pool of water saturated with Epsom salt. The environment is designed to minimize external stimulation via multiple channels including sound, light, and temperature.
有源比较器:Documentary Condition
Participants will watch two one-hour documentaries in a relaxing environment approximately seven days apart.
Participants will sit in a quiet room and watch a documentary.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Adverse effects
大体时间:From baseline to post-intervention seven day follow-up
Safety will be assessed using adverse events reported directly to study staff and adverse effects reported on the Floatation-REST effects checklist after each Floatation-REST or comparator session. As a proxy of safety, adverse effects will be calculated for each participant as the number of instances during the study in which the participant reports an increase above mild for any negatively experienced effect on the checklist.
From baseline to post-intervention seven day follow-up
Dropout Rate
大体时间:Baseline through seven day post-intervention follow up
As a proxy for tolerability, dropout rate for each arm = (# of subjects who are withdrawn from the study)/(# participants in specific arm).
Baseline through seven day post-intervention follow up

次要结果测量

结果测量
措施说明
大体时间
Burnout Effects of Floatation-REST
大体时间:Baseline through seven day post-intervention follow up
Burnout measured using the MBI-HSS questionnaire after each experimental session and at follow-up time points
Baseline through seven day post-intervention follow up
Perceived Stress Effects of Floatation-REST
大体时间:Baseline through seven day post-intervention follow up
Perceived stress measured using the Perceived Stress Scale after each experimental session and at follow-up time points
Baseline through seven day post-intervention follow up
Moral Injury Effects of Floatation-REST
大体时间:Baseline through seven day post-intervention follow up
Moral injury measured using the Moral Injury and Distress Scale after each experimental session and at follow-up time points
Baseline through seven day post-intervention follow up
Depressive Symptomatology Effects of Floatation-REST
大体时间:Baseline through seven day post-intervention follow up
Depressive symptoms measured using the Quick Inventory of Depressive Symptomatology (QIDS-SR) after each experimental session and at follow-up time points
Baseline through seven day post-intervention follow up

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月10日

初级完成 (估计的)

2026年12月1日

研究完成 (估计的)

2026年12月1日

研究注册日期

首次提交

2026年7月8日

首先提交符合 QC 标准的

2026年7月13日

首次发布 (实际的)

2026年7月17日

研究记录更新

最后更新发布 (实际的)

2026年7月17日

上次提交的符合 QC 标准的更新

2026年7月13日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅